Probiotics: A new way to fight bacterial pulmonary infections?

Autor: Geneviève Héry-Arnaud, Youenn Alexandre, R. Le Berre, F. Le Gall, S. Boisramé-Gastrin, Sophie Vallet, S. Gouriou, G. Le Blay
Přispěvatelé: Laboratoire Universitaire de Biodiversité et Ecologie Microbienne (LUBEM), Université de Brest (UBO), Laboratoire de microbiologie des environnements extrêmophiles (LM2E), Centre National de la Recherche Scientifique (CNRS)-Université de Brest (UBO)-Institut Français de Recherche pour l'Exploitation de la Mer (IFREMER), Laboratoire de Parasitologie et Mycologiede [CHRU Brest], Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Département de Médecine Interne et Pneumologie [Brest] (DMIP - Brest)
Rok vydání: 2014
Předmět:
medicine.medical_specialty
Cystic Fibrosis
medicine.drug_class
Respiratory System
Antibiotics
Hospital-acquired pneumonia
Cystic fibrosis
Rational use
World health
Immunomodulation
Mice
Pulmonary Disease
Chronic Obstructive
03 medical and health sciences
Double-Blind Method
Species Specificity
Community-acquired pneumonia
[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases
Pneumonia
Bacterial
medicine
Animals
Humans
Intensive care medicine
Randomized Controlled Trials as Topic
030304 developmental biology
Cross Infection
0303 health sciences
Respiratory tract infections
030306 microbiology
business.industry
Microbiota
Probiotics
Pneumonia
Ventilator-Associated
Quorum Sensing
medicine.disease
3. Good health
Community-Acquired Infections
Penicillin
Infectious Diseases
Probiotics No items selected
Immune System
[SDE]Environmental Sciences
Disease Susceptibility
business
medicine.drug
Zdroj: Médecine et Maladies Infectieuses
Médecine et Maladies Infectieuses, Elsevier Masson, 2014, 44 (1), pp.9-17. ⟨10.1016/j.medmal.2013.05.001⟩
ISSN: 0399-077X
DOI: 10.1016/j.medmal.2013.05.001
Popis: International audience; Antibiotics, of which Fleming has identified the first representative, penicillin, in 1928, allowed dramatical improvement of the treatment of patients presenting with infectious diseases. However, once an antibiotic is used, resistance may develop more or less rapidly in some bacteria. It is thus necessary to develop therapeutic alternatives, such as the use of probiotics, defined by the World Health Organization (WHO) as "micro-organisms which, administered live and in adequate amounts, confer a benefit to the health of the host". The scope of these micro-organisms is broad, concerning many areas including that of infectious diseases, especially respiratory infections. We describe the rational use of probiotics in respiratory tract infections and detail the results of various clinical studies describing the use of probiotics in the management of respiratory infections such as nosocomial or community acquired pneumonia, or on specific grounds such as cystic fibrosis. The results are sometimes contradictory, but the therapeutic potential of probiotics seems promising. Implementing research to understand their mechanisms of action is critical to conduct therapeutic tests based on a specific rational for the strains to be used, the dose, as well as the chosen mode and rhythm of administration
Databáze: OpenAIRE
Externí odkaz: